Thus, we aimed to evaluate the effect of DPP-4 inhibitors on CVD risk factors: central obesity, lipidemia, hsCRP, glycaemia and blood pressure with a special emphasis on AS and related parameters, i.e. central pulse pressure (PP), central blood pressure (cBP) and pulse wave velocity (PWV) in metabolically well regulated T2DM patients. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.